Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCRI CLL210: ofatumumab, dexamethasone and lenalidomide for high-risk CLL
2010-019575-29Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab, dexamethasone and lenalidomide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Liverpool. Primary endpoint: Complete response rate following induction therapy. Started Feb 2011; status: completed.
02
Drugs
ofatumumabdexamethasonelenalidomide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2010-019575-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019575-29.